 |
MediciNova to Present At the Rodman and Renshaw 5th Annual Global Healthcare Conference
SAN DIEGO, May 13, 2008 ( PRIME NEWSWIRE)- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that Shintaro Asako, Chie
Securities Class Action Against Discovery Labs is Dismissed
These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made, including, without limitation, the risks that: Discovery Labs may be unable to ti
Nanosphere Announces First Quarter 2008 Results;
Nanosphere, Inc. Statements of Operations ( Unaudited) Three Month Periods Ended March 31, 2008 2007 ( As restated) REVENUE: Grant and contract revenue $ 272,612 $ 223,258 Product sales 303,404 46,645 Total revenue 576,016 269,903 COSTS AND
EDAP Adds Premiere M.D. Anderson Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial
LYON, France, May 13, 2008 ( PRIME NEWSWIRE)- EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that The University of Texas M.D. Anderson Cancer Center in Houston, Texas received Institutional Review Board ( IRB) ap
Hana Biosciences Announces First Quarter 2008 Results
CONDENSED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS ( Unaudited) Three Months Ended March 31, 2008 2007 Operating expenses: General and administrative $ 1,900,920 $ 3,346,985 Research and development 4,264,332 5,237,904 Total op
Kraig Biocraft Laboratories, Inc. to File 10 Q With the SEC Later Today for the First Quarter of 200
10 Q Filing for Quarter Ending on March 31, 2008 Covers the First Quarter During Which the Company's Shares Have Been Publicly Traded Expansion of Kraig Research Initiative for 2008 LANSING, Mich., May 13, 2008 ( PRIME NEWSWIRE)- Kraig Bioc
Hemispherx Biopharma, Inc. Releases Financial Results for the Three Months Ended March 31, 2008
Clinical trials for other potential indications of the approved biologic Alferon N Injection ( r) do not imply that the product will ever be specifically approved commercially for these other treatment indications; Similarly, the completion
Chelsea Therapeutics Reports First Quarter 2008 Results
AND SUBSIDIARY ( A Development Stage Company) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( unaudited) For the three months ended March 31, 2008 2007 Operating expenses: Research and development $ 6,504,832 $ 3,167,289 Sales and marketi
MediciNova Reports First Quarter 2008 Results
( a development stage company) CONSOLIDATED STATEMENTS OF OPERATIONS ( Unaudited) Period from Three months ended September 26, March 31, 2000 ( inception) to March 31, 2008 2007 2008 Revenues $- $- $ 1,558,227 Operating expenses: Cost of re
Aastrom Reports Third Quarter Fiscal Year 2008 Financial Results
( Unaudited) ( In thousands, except per share amounts) CONSOLIDATED STATEMENTS OF OPERATIONS DATA: Quarter ended Nine months ended March 31, March 31, 2007 2008 2007 2008 REVENUES: Total revenues $ 258 $ 202 $ 520 $ 373 COSTS AND EXPENSES:
Meridian Bioscience to Present At the Nasdaq 21st Investor Program, London
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies.
Proton Laboratories Announces Its Recently Licensed and Proprietary Cooling Tower Process Utilizing
a biotechnology company that develops practical uses for electrolyzed water, is pleased to announce that it has obtained an exclusive U.S. distribution license from its Japanese engineering group- Innovative Design and Technology ( IDT)- fo
Generex Biotechnology Announces That It Has Produced MetControl, the Company's Proprietary Metformin
WORCESTER, Mass., May 12, 2008 ( PRIME NEWSWIRE)- Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has produced clinical samples of MetContr
Icagen to Present At the Rodman & Renshaw 5th Annual Global Healthcare Conference On May 19, 2008
These risk factors include risks as to the Company's history of net losses and how long the Company will be able to operate on its existing capital resources; the Company's ability to raise additional funding; the Company's ability to maint
XOMA Reports First Quarter 2008 Financial Results
CONDENSED CONSOLIDATED BALANCE SHEETS ( in thousands, except share and per share amounts) March 31, Dec. 31, 2008 2007 ( unaudited) ASSETS Current assets: Cash and cash equivalents $ 8,815 $ 22,500 Short-term investments 10,220 16,067 Restr
XOMA Refinances Royalty-Based Loan Facility for $55 Million
These and other risks, including those related to the results of discovery and pre-clinical testing; the timing or results of pending and future clinical trials ( including the design and progress of clinical trials; safety and efficacy of
Semi-Annual Changes to the NASDAQ Biotechnology Index
The Industry Classification Benchmark ( " ICB") is jointly owned by FTSE International Limited ( " FTSE") and Dow Jones & Company, Inc.
VirtualScopics Announces Results of Annual Stockholders' Meeting
The company's Chief Executive Officer, Jeff Markin and Chief Financial Officer, Molly Henderson presented a business overview which highlighted the significant progress made by the company over the past four years as well as its plans for t
Sonus Pharmaceuticals, Inc. Receives Staff Determination Letter From Nasdaq
BOTHELL, Wash., May 9, 2008 ( PRIME NEWSWIRE)- Sonus Pharmaceuticals, Inc. today announced that it has received a determination letter from The Nasdaq Stock Market ( " Nasdaq") dated May 6, 2008, indicating that the Company has failed to re
Universal Detection Technology's Anti-Microbial Washing Additive Proves Effective Against the Re-Gro
LOS ANGELES, May 9, 2008 ( PRIME NEWSWIRE)- Universal Detection Technology ( www.udetection. com), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of
LBO Capital Corp. Signs Agreement to Acquire Ecoplastifuel, Inc.
Corporate Profile LBO Capital Corp., founded in 1988, and its subsidiaries Global Tech International, Inc and Advanced Digital Components, Inc., strive to acquire intellectual property and technology; and further, actively seek to identify
Znomics and University of Utah Launch Collaborative Drug Discovery Program in Oncology, Autoimmune D
For more information visit our website at www.znomics. com CONTACT: Znomics, Inc. Richard Sessions, Chief Executive Officer 503 827-5271 X102 sessions@ znomics. com Kerry Rea, Chief Financial Officer 503 827-5271 X101 k. rea@ znomics. com P
Athersys Reports 2008 First Quarter Results
Revenues of $ 0.8 million and a net loss of $ 4.7 million were recorded for the quarter ended March 31, 2008;* A Phase I clinical trial of ATHX-105, a highly selective 5HT 2c agonist being developed as an obesity therapy, was completed with
Nabi Biopharmaceuticals Announces First Quarter 2008 Financial Results
Nabi Biopharmaceuticals CONDENSED CONSOLIDATED BALANCE SHEETS ( Unaudited) ( In thousands) March 29, Dec. 29, 2008 2007 ASSETS Current assets: Cash and cash equivalents $ 197,724 $ 217,606 Marketable securities- 1,600 Prepaid expenses and o
QIAGEN to Present At Bank of America 2008 Health Care Conference
Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations ( including the effects of currency fluctuations and risks of dependency on logistics), variability of ope
|
|
|
|
|
|
|
|
|
